Elan, the Irish drug company, is fending off a hostile bid by Royalty Pharma by buying royalties itself ‑ a $1bn investment in Theverance, a speciality respiratory drug company. Lex’s Stuart Kirk and Vincent Boland discuss whether the strategy will work.
For more video content from the Financial Times, visit http://www.FT.com/video
